{"id":103705,"date":"2025-04-29T13:10:03","date_gmt":"2025-04-29T11:10:03","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/"},"modified":"2025-04-29T13:24:10","modified_gmt":"2025-04-29T11:24:10","slug":"gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/","title":{"rendered":"Gisela Lorente, CEO of Aptadel Therapeutics: &#8220;In the last 30 years, there has been no significant innovation for the treatment of Ewing&#8217;s sarcoma&#8221;"},"content":{"rendered":"<p>With a career that combines research and innovation management, <strong>Gisela Lorente<\/strong> leads <a href=\"https:\/\/www.pcb.ub.edu\/en\/empresa\/aptadel-therapeutics\/\" target=\"_blank\" rel=\"noopener\">Aptadel Therapeutics<\/a>, a spin-off born from IDIBELL focused on developing innovative therapies based on RNA aptamers. These molecules can be conjugated with therapeutic agents to treat pediatric cancers, such as Ewing\u2019s sarcoma, a type of childhood tumor with a low life expectancy that affects bones and soft tissues. \u201cIn the last 30 years, there has been no significant innovation in the treatment of Ewing&#8217;s sarcoma,\u201d says <strong>Lorente<\/strong>.<\/p>\n<p>RNA therapies represent a revolutionary approach to cancer treatment, as they allow for the specific targeting of tumor cells without damaging healthy tissues. Aptamers, in particular, offer notable advantages over other drug delivery molecules, especially in the field of oncology. \u201cOur main program consists of an aptamer conjugated with siRNA, which has antimetastatic capabilities and inhibits tumor growth,\u201d explains the CEO.<\/p>\n<p>In this interview, recorded during the biannual networking meeting at the Barcelona Science Park, <strong>Gisela Lorente<\/strong> reflects on the entrepreneurial ecosystem, the value of scientific translation, and the lessons learned from her journey as a founder and scientist.<\/p>\n<p><iframe loading=\"lazy\" title=\"Coffee Connection: entrevista a Gisela Lorente, CEO de Aptadel Therapeutics\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/arBuBtDShPA?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"<p>With a career that combines research and innovation management, Gisela Lorente leads Aptadel Therapeutics, a spin-off born from IDIBELL focused on developing innovative therapies based on RNA aptamers. These molecules&#8230;<\/p>\n","protected":false},"author":1,"featured_media":103701,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[38],"tags":[256],"class_list":["post-103705","post","type-post","status-publish","format-standard","has-post-thumbnail","category-pcb-en","tag-aptadel-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gisela Lorente, CEO of Aptadel Therapeutics: &quot;In the last 30 years, there has been no significant innovation for the treatment of Ewing&#039;s sarcoma&quot; - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"Gisela Lorente leads Aptadel Therapeutics, a spin-off from IDIBELL focused on the development of therapies based on RNA aptamers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gisela Lorente, CEO of Aptadel Therapeutics: &quot;In the last 30 years, there has been no significant innovation for the treatment of Ewing&#039;s sarcoma&quot; - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Gisela Lorente leads Aptadel Therapeutics, a spin-off from IDIBELL focused on the development of therapies based on RNA aptamers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-29T11:10:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-29T11:24:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-6.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Gisela Lorente, CEO of Aptadel Therapeutics: &#8220;In the last 30 years, there has been no significant innovation for the treatment of Ewing&#8217;s sarcoma&#8221;\",\"datePublished\":\"2025-04-29T11:10:03+00:00\",\"dateModified\":\"2025-04-29T11:24:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\\\/\"},\"wordCount\":206,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Adobe-Express-file-6.png\",\"keywords\":[\"Aptadel\"],\"articleSection\":[\"PCB\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\\\/\",\"name\":\"Gisela Lorente, CEO of Aptadel Therapeutics: \\\"In the last 30 years, there has been no significant innovation for the treatment of Ewing's sarcoma\\\" - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Adobe-Express-file-6.png\",\"datePublished\":\"2025-04-29T11:10:03+00:00\",\"dateModified\":\"2025-04-29T11:24:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"description\":\"Gisela Lorente leads Aptadel Therapeutics, a spin-off from IDIBELL focused on the development of therapies based on RNA aptamers.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Adobe-Express-file-6.png\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Adobe-Express-file-6.png\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gisela Lorente, CEO of Aptadel Therapeutics: &#8220;In the last 30 years, there has been no significant innovation for the treatment of Ewing&#8217;s sarcoma&#8221;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gisela Lorente, CEO of Aptadel Therapeutics: \"In the last 30 years, there has been no significant innovation for the treatment of Ewing's sarcoma\" - Parc Cient\u00edfic de Barcelona","description":"Gisela Lorente leads Aptadel Therapeutics, a spin-off from IDIBELL focused on the development of therapies based on RNA aptamers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/","og_locale":"en_US","og_type":"article","og_title":"Gisela Lorente, CEO of Aptadel Therapeutics: \"In the last 30 years, there has been no significant innovation for the treatment of Ewing's sarcoma\" - Parc Cient\u00edfic de Barcelona","og_description":"Gisela Lorente leads Aptadel Therapeutics, a spin-off from IDIBELL focused on the development of therapies based on RNA aptamers.","og_url":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2025-04-29T11:10:03+00:00","article_modified_time":"2025-04-29T11:24:10+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-6.png","type":"image\/png"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Written by":"adminpcb","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Gisela Lorente, CEO of Aptadel Therapeutics: &#8220;In the last 30 years, there has been no significant innovation for the treatment of Ewing&#8217;s sarcoma&#8221;","datePublished":"2025-04-29T11:10:03+00:00","dateModified":"2025-04-29T11:24:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/"},"wordCount":206,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-6.png","keywords":["Aptadel"],"articleSection":["PCB"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/","url":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/","name":"Gisela Lorente, CEO of Aptadel Therapeutics: \"In the last 30 years, there has been no significant innovation for the treatment of Ewing's sarcoma\" - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-6.png","datePublished":"2025-04-29T11:10:03+00:00","dateModified":"2025-04-29T11:24:10+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"description":"Gisela Lorente leads Aptadel Therapeutics, a spin-off from IDIBELL focused on the development of therapies based on RNA aptamers.","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-6.png","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-6.png","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/gisela-lorente-ceo-of-aptadel-therapeutics-in-the-last-30-years-there-has-been-no-significant-innovation-for-the-treatment-of-ewings-sarcoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Gisela Lorente, CEO of Aptadel Therapeutics: &#8220;In the last 30 years, there has been no significant innovation for the treatment of Ewing&#8217;s sarcoma&#8221;"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/103705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=103705"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/103705\/revisions"}],"predecessor-version":[{"id":103707,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/103705\/revisions\/103707"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/103701"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=103705"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=103705"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=103705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}